fbpx
June 24, 2024

Subcutaneous efgartigimod alfa hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) has been shown to reduce relapse risk in chronic inflammatory demyelinating polyneuropathy (CIDP). Subcutaneous efgartigimod alfa hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) has been shown to reduce relapse risk in chronic inflammatory demyelinating polyneuropathy (CIDP).

The US Food and Drug Administration (FDA) has approved the combination of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) for treatment of adults with chronic inflammatory […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0